Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infectionsAMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGYIF8.42022-12-0132PRE
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal CandidiasisCLINICAL INFECTIOUS DISEASESIF7.32020-08-2043OAAI
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*BRITISH JOURNAL OF DERMATOLOGYIF9.62020-07-1332PREAI
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasisAMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGYIF8.42018-06-0163PREAI
Results from a phase 2, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of VT 1161 oral tablets in the treatment of patients with recurrent vulvovaginal candidiasisAMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGYIF8.42017-12-016PREAI
Efficacy and safety of oral VT-11611 in a randomized phase 2a study in patients with acute vulvovaginal candidiasis: six-month follow-upAMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGYIF8.42015-12-011PREAI
A Randomized, Double-Blind Phase 2 Study Comparing the Efficacy and Safety of an Oral Fusidic Acid Loading-Dose Regimen to Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCLINICAL INFECTIOUS DISEASESIF7.32011-06-0143OAAI
Pharmacokinetics and Safety of Single, Multiple, and Loading Doses of Fusidic Acid in Healthy SubjectsCLINICAL INFECTIOUS DISEASESIF7.32011-05-0522OAAI
Pharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult SubjectsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52011-05-0156OAAI
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathyAMERICAN JOURNAL OF NEPHROLOGYIF3.22007-09-06216PREAI
Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drugDIABETOLOGIAIF10.22003-09-0124OAAI
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic ratKIDNEY INTERNATIONALIF12.62002-03-01355OAAI
Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic ratsDIABETES RESEARCH AND CLINICAL PRACTICEIF7.41999-02-0138PREAI
Role of the Maillard reaction in aging of tissue proteins - Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteinsJOURNAL OF BIOLOGICAL CHEMISTRYIF3.91998-07-01320OAAI
The serum concentration of the advanced glycation end-product N-epsilon-(carboxymethyl)lysine is increased in uremiaKIDNEY INTERNATIONALIF12.61997-10-01104OAAI
Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivoJOURNAL OF BIOLOGICAL CHEMISTRYIF3.91997-07-01101OAAI
N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteinsBIOCHEMICAL JOURNALIF4.31997-06-01606OAAI